Aadi Bioscience: Drug Recall

Recall #D-0059-2023 · 10/13/2022

Class III: Low Risk

Recall Details

Recall Number
D-0059-2023
Classification
Class III
Product Type
Drug
Recalling Firm
Aadi Bioscience
Status
Terminated
Date Initiated
10/13/2022
Location
Pacific Palisades, CA, United States
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,333 vials

Reason for Recall

Failed Stability Specifications

Product Description

Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.

Distribution Pattern

Within the U.S Market - PA, AL, KY, TN

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.